Related Experiment Video
Updated: Dec 11, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Systematic Characterization of the Biodistribution of the Oncolytic Virus M1
Jing Cai1, Wenbo Zhu1, Yuan Lin1
1Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
Abstract:
Oncolytic viruses are emerging as important tools for immunotherapy for cancer treatment; however, most of the clinically tested oncolytic candidates are still administered by intratumoral injection, and new viruses capable of intravenous injection are urgently needed. The M1 virus is a positive-sense single-stranded RNA virus that belongs to the alphavirus family, and it was identified as an oncolytic virus that can selectively replicate in and kill tumor cells after intravenous injection. To further develop M1 for clinical research through intravenous injection, we systematically investigated the biodistribution characteristics of the M1 virus in normal rats, cynomolgus monkeys, and tumor-bearing immunocompromised mice. The data showed that the M1 virus was eliminated gradually from normal tissue but replicated and increased rapidly in tumor tissue. More importantly, the virus also infiltrated the blood-brain barrier and specifically replicated in and killed malignant glioma in immunocompetent mice. Our data proved the tumor selectivity and safety of the M1 virus, supporting its further clinical development.
Insights
The M1 virus, an oncolytic alphavirus, shows promise for cancer immunotherapy. It selectively targets and replicates in tumors after intravenous injection, demonstrating safety and efficacy, even crossing the blood-brain barrier to treat glioma.
Area of Science:
- Virology
- Immunotherapy
- Oncolytic Virotherapy
Background:
- Oncolytic viruses are crucial for cancer immunotherapy.
- Intratumoral injection limits current oncolytic virus applications.
- Development of viruses for intravenous administration is essential.
Purpose of the Study:
- To evaluate the M1 virus, an alphavirus, for intravenous cancer therapy.
- To investigate the biodistribution and tumor selectivity of the M1 virus.
- To assess the safety and efficacy of M1 virus in preclinical models.
Main Methods:
- Systematic biodistribution studies of M1 virus in rats, monkeys, and mice.
- Assessment of M1 virus replication in normal versus tumor tissues.
- Evaluation of M1 virus efficacy against malignant glioma in immunocompetent mice.
Main Results:
- M1 virus demonstrated gradual elimination from normal tissues.
- M1 virus showed rapid replication and accumulation in tumor tissues.
- M1 virus successfully infiltrated the blood-brain barrier and targeted glioma.
Conclusions:
- The M1 virus exhibits tumor selectivity and safety for intravenous administration.
- M1 virus shows potential for treating various cancers, including brain tumors.
- Further clinical development of M1 virus for cancer immunotherapy is warranted.
